{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:08:52Z","timestamp":1761512932153,"version":"3.38.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.jpba.2011.01.040","type":"journal-article","created":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T09:11:22Z","timestamp":1297069882000},"page":"487-493","source":"Crossref","is-referenced-by-count":8,"title":["Simultaneous determination of alfentanil and midazolam in human plasma using liquid chromatography and tandem mass spectrometry"],"prefix":"10.1016","volume":"55","author":[{"given":"Thomas","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"London","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan D.","family":"Kharasch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2011.01.040_bib0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0010","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMra032424","article-title":"Drug metabolism and variability among patients in drug response","volume":"352","author":"Wilkinson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2011.01.040_bib0015","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbagen.2006.09.024","article-title":"The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks","volume":"1770","author":"Plant","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jpba.2011.01.040_bib0020","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2165\/00003088-200342130-00001","article-title":"Dietary effects on drug metabolism and transport","volume":"42","author":"Harris","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2011.01.040_bib0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-200004000-00001","article-title":"Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes","volume":"10","author":"Streetman","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.jpba.2011.01.040_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1067\/mcp.2001.116891","article-title":"Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential-toward a consensus","volume":"70","author":"Tucker","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1067\/mcp.2003.23","article-title":"An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity","volume":"73","author":"Rogers","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0040","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.1992.84","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite a-hydroxymidazolam in healthly volunteers","volume":"51","author":"Mandema","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2010.482929","article-title":"Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?","volume":"6","author":"Kirwan","year":"2010","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"key":"10.1016\/j.jpba.2011.01.040_bib0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000542-199707000-00006","article-title":"The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions","volume":"87","author":"Kharasch","year":"1997","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpba.2011.01.040_bib0055","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1177\/00912709922008290","article-title":"Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance","volume":"39","author":"Kharasch","year":"1999","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2011.01.040_bib0060","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1067\/mcp.2003.30","article-title":"Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity","volume":"73","author":"Kharasch","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0065","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clpt.2004.07.006","article-title":"Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass CYP3A activity. Noninvasive assessment using pupillary miosis","volume":"76","author":"Kharasch","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1213\/00000539-198701000-00009","article-title":"Pharmacokinetics of alfentanil in chronic renal failure","volume":"66","author":"Chauvin","year":"1987","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jpba.2011.01.040_bib0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1213\/00000539-198610000-00001","article-title":"The influence of hepatic plasma flow on alfentanil plasma concentration plateaus achieved with an infusion model in humans: measurement of alfentanil hepatic extraction coefficient","volume":"65","author":"Chauvin","year":"1986","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.jpba.2011.01.040_bib0080","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00000542-198810000-00012","article-title":"Alfentanil pharmacokinetics and metabolism in humans","volume":"69","author":"Meuldermans","year":"1988","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpba.2011.01.040_bib0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","article-title":"Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam","volume":"82","author":"Kharasch","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2011.01.040_bib0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/mi.5.3.3","article-title":"CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition","volume":"5","author":"Kharasch","year":"2005","journal-title":"Mol. Interv."},{"key":"10.1016\/j.jpba.2011.01.040_bib0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0378-4347(94)00201-0","article-title":"Determination of alfentanil and noralfentanil in human plasma by gas chromatography\u2013mass spectrometry","volume":"658","author":"Mautz","year":"1994","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2011.01.040_bib0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jchromb.2004.01.044","article-title":"Highly sensitive gas chromatographic\u2013mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfentanil and their major metabolites in urine of opioid exposed workers","volume":"804","author":"Van Nimmen","year":"2004","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2011.01.040_bib0105","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/0378-4347(87)80317-1","article-title":"Determination of fentanyl and alfentanil in plasma by high-performance liquid chromatography with ultraviolet detection","volume":"419","author":"Kumar","year":"1987","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.jpba.2011.01.040_bib0110","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0091270004269705","article-title":"Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination","volume":"45","author":"Kharasch","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2011.01.040_bib0115","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0091270005282629","article-title":"Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions","volume":"45","author":"Baririan","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2011.01.040_bib0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.forsciint.2009.01.013","article-title":"Simultaneous screening and quantification of 25 opioid drugs in post-mortem blood and urine by liquid chromatography\u2013tandem mass spectrometry","volume":"186","author":"Gergov","year":"2009","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.jpba.2011.01.040_bib0125","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/jssc.201000330","article-title":"A comprehensive LC\u2013MS-based quantitative analysis of fentanyl-like drugs in plasma and urine","volume":"33","author":"Cooreman","year":"2010","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2011.01.040_bib0130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1067\/mcp.2001.119994","article-title":"A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans","volume":"70","author":"Phimmasone","year":"2001","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708511000665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708511000665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T12:18:01Z","timestamp":1740917881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708511000665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0731708511000665"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2011.01.040","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}